Miwei Biotech-B (02493): The clinical trial application for 9MW5211 injection for the treatment of vitiligo has been approved.

Zhijun Finance and Economics APP news, Maivei Biology-B (02493) announced that recently, the company received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for MW5211 injection for vitiligo indications has been approved. Previously, its clinical trial applications for inflammatory bowel disease (IBD) indications have been approved by the National Medical Products Administration and FDA, and clinical trial applications for multiple sclerosis (MS) and type 1 diabetes (T1DM) indications have been approved by the National Medical Products Administration. The company is also actively advancing the clinical trial application work for several other indications, and some indications have been accepted by the National Medical Products Administration.